Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of roflumilast in mild cognitive impairment or mild dementia
NL-OMON54654Phase 2Completed
- Sponsor
- Maastricht University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roflumilast in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by Maastricht University. Started Jun 2021; status: completed.
02
Drugs
roflumilast
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON54654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54654.